A promising therapeutic strategy for CMT1A is the use of synthetic DNA (antisense oligonucleotides) and silencing RNA molecules to suppress the expression of PMP22 RNA. Here, PMP22 is linked to Charcot-Marie-Tooth disease type 1A.